Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine trial in children with centronuclear myopathy in Southern Africa
PACTR202103700536808Recruiting
- Sponsor
- University College London
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of pyridostigmine in centronuclear myopathy (CNM) and congenital myopathy (2 arms), sponsored by University College London. Primary endpoints: Muscle strength response, 6-minute walk test and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
pyridostigmine
03
Conditions
centronuclear myopathy (CNM)congenital myopathy
Beyond the preview
Go deeper on PACTR202103700536808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202103700536808.